董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erica J. Rogers | 女 | Director | 57 | 11.73万美元 | 未持股 | 2021-01-31 |
| David Lamond | 男 | Director | 45 | 11.73万美元 | 未持股 | 2021-01-31 |
| Steve Tablak | 男 | Director | 61 | 5.67万美元 | 未持股 | 2021-01-31 |
| Tuff Yen | 男 | Director | 58 | 未披露 | 未持股 | 2021-01-31 |
| Erik T. Engelson | 男 | President, Chief Executive Officer and Director | 61 | 77.50万美元 | 未持股 | 2021-01-31 |
| Debkishore Mitra | -- | Chief Technology Officer and Director | 34 | 62.69万美元 | 未持股 | 2021-01-31 |
| Lior Susan | 男 | Director | 37 | 未披露 | 未持股 | 2021-01-31 |
| Sandra A. Gardiner | 女 | Director | 55 | 11.73万美元 | 未持股 | 2021-01-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erik T. Engelson | 男 | President, Chief Executive Officer and Director | 61 | 77.50万美元 | 未持股 | 2021-01-31 |
| Daniel George | 男 | Chief Financial Officer and Treasurer | 51 | 未披露 | 未持股 | 2021-01-31 |
| Hansgregory Charles Hartmann | 男 | Chief Operating Officer | 63 | 未披露 | 未持股 | 2021-01-31 |
| Debkishore Mitra | -- | Chief Technology Officer and Director | 34 | 62.69万美元 | 未持股 | 2021-01-31 |
| Tamanna Prashar | 女 | Vice President, Global Supply Chain, Operations and Quality | 40 | 未披露 | 未持股 | 2021-01-31 |
| Kelly Lewis Brezoczky | 女 | Executive Vice President, Commercialization, Regulatory, Clinical and Business Development | 57 | 73.61万美元 | 未持股 | 2021-01-31 |
董事简历
中英对照 | 中文 | 英文- Erica J. Rogers
-
EricaJ.Rogers自2020年9月以来一直担任我们的董事会成员。Rogers女士自2012年10月起担任Silk Road Medical Inc.（一家医疗设备制造商）的总裁兼首席执行官和董事会成员。Rogers之前从2010年6月到2012年10月担任Medicines360（一家非盈利制药公司，为女性开发药物和设备）首席运营官。Rogers女士于2008年12月至2010年3月担任量子点技术公司NanoSys，Inc.的执行Vice President。在此之前，Rogers女士创立并担任Allux Medical（一家医疗设备公司）的首席执行官，并共同创立VisioGen（一家眼科医疗设备公司，于2009年被Abbott Medical Optics收购）。她此前曾任职Target Therapeutics Inc.（医疗设备制造商）的神经血管营销，以及Boston Scientific公司（医疗设备制造商）的外周血管销售和销售培训。Rogers女士目前在Sight Sciences，Inc.（一家医疗设备公司）的董事会任职。Rogers女士在圣地亚哥州立大学（San Diego State University）获得动物学学士学位。
Erica J. Rogers has served as a member of our board of directors since September 2020. Ms. Rogers has served as President and Chief Executive Officer and a member of the board of directors of Silk Road Medical Inc., a medical equipment manufacturer, since October 2012. Ms. Rogers previously served as Chief Operating Officer of Medicines360 a non-profit pharmaceutical company developing drugs and devices for women from June 2010 to October 2012. Ms. Rogers was an Executive Vice President at Nanosys, Inc., a quantum dot technology company, from December 2008 to March 2010. Prior to that, Ms. Rogers founded and was Chief Executive Officer of Allux Medical, a medical device company, and co-founded Visiogen, an ophthalmic medical device company which was acquired by Abbott Medical Optics in 2009. She worked previously in neurovascular marketing at Target Therapeutics Inc., a medical equipment manufacturer, and peripheral vascular sales and sales training at Boston Scientific, a medical device manufacturer. Ms. Rogers currently serves on the board of directors of Sight Sciences, Inc., a medical device company. Ms. Rogers received a B.S. in zoology from San Diego State University. - EricaJ.Rogers自2020年9月以来一直担任我们的董事会成员。Rogers女士自2012年10月起担任Silk Road Medical Inc.（一家医疗设备制造商）的总裁兼首席执行官和董事会成员。Rogers之前从2010年6月到2012年10月担任Medicines360（一家非盈利制药公司，为女性开发药物和设备）首席运营官。Rogers女士于2008年12月至2010年3月担任量子点技术公司NanoSys，Inc.的执行Vice President。在此之前，Rogers女士创立并担任Allux Medical（一家医疗设备公司）的首席执行官，并共同创立VisioGen（一家眼科医疗设备公司，于2009年被Abbott Medical Optics收购）。她此前曾任职Target Therapeutics Inc.（医疗设备制造商）的神经血管营销，以及Boston Scientific公司（医疗设备制造商）的外周血管销售和销售培训。Rogers女士目前在Sight Sciences，Inc.（一家医疗设备公司）的董事会任职。Rogers女士在圣地亚哥州立大学（San Diego State University）获得动物学学士学位。
- Erica J. Rogers has served as a member of our board of directors since September 2020. Ms. Rogers has served as President and Chief Executive Officer and a member of the board of directors of Silk Road Medical Inc., a medical equipment manufacturer, since October 2012. Ms. Rogers previously served as Chief Operating Officer of Medicines360 a non-profit pharmaceutical company developing drugs and devices for women from June 2010 to October 2012. Ms. Rogers was an Executive Vice President at Nanosys, Inc., a quantum dot technology company, from December 2008 to March 2010. Prior to that, Ms. Rogers founded and was Chief Executive Officer of Allux Medical, a medical device company, and co-founded Visiogen, an ophthalmic medical device company which was acquired by Abbott Medical Optics in 2009. She worked previously in neurovascular marketing at Target Therapeutics Inc., a medical equipment manufacturer, and peripheral vascular sales and sales training at Boston Scientific, a medical device manufacturer. Ms. Rogers currently serves on the board of directors of Sight Sciences, Inc., a medical device company. Ms. Rogers received a B.S. in zoology from San Diego State University.
- David Lamond
-
David Lamond自2020年2月以来一直担任我们的董事会成员。自2016年4月起，Lamond先生一直担任投资公司En Pointe LLC的总裁。2011年11月至2016年6月，他担任对冲基金Lamond Capital Partners LLC的总裁，首席执行官和首席投资官。他自2018年9月起担任生物技术公司Applied Molecular TransportInc.的董事会成员，自2020年2月起担任医疗器械公司Inquis Clinical Research Ltd.的董事会成员，自2015年12月起担任生物制药公司Cortexyme，Inc.的董事会成员，自2015年12月起担任基因治疗公司Genelpis的董事会成员，自2019年8月起担任Arrinex，Inc.（一家医疗设备公司，现为史赛克公司的子公司）的董事会成员。Lamond先生拥有杜克大学（Duke University）历史学学士学位和杜克法学院（Duke Law School）法学博士学位。
David Lamond,serves on the board of directors of EG 427, a biotechnology company, Inquis Medical, a medical device company and Windfall Data, an analytics company. He previously served on the board of Applied Molecular Transport, a biotechnology company, and Arrinex, a medical device company until its acquisition by Stryker Corporation in February 2019. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School. - David Lamond自2020年2月以来一直担任我们的董事会成员。自2016年4月起，Lamond先生一直担任投资公司En Pointe LLC的总裁。2011年11月至2016年6月，他担任对冲基金Lamond Capital Partners LLC的总裁，首席执行官和首席投资官。他自2018年9月起担任生物技术公司Applied Molecular TransportInc.的董事会成员，自2020年2月起担任医疗器械公司Inquis Clinical Research Ltd.的董事会成员，自2015年12月起担任生物制药公司Cortexyme，Inc.的董事会成员，自2015年12月起担任基因治疗公司Genelpis的董事会成员，自2019年8月起担任Arrinex，Inc.（一家医疗设备公司，现为史赛克公司的子公司）的董事会成员。Lamond先生拥有杜克大学（Duke University）历史学学士学位和杜克法学院（Duke Law School）法学博士学位。
- David Lamond,serves on the board of directors of EG 427, a biotechnology company, Inquis Medical, a medical device company and Windfall Data, an analytics company. He previously served on the board of Applied Molecular Transport, a biotechnology company, and Arrinex, a medical device company until its acquisition by Stryker Corporation in February 2019. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School.
- Steve Tablak
-
Steve Tablak自2019年12月起担任我们的董事会成员。Tablak先生自2017年8月起担任分子诊断公司Inflamatix，Inc.的董事会成员。2015年9月至2017年2月，他担任罗氏分子系统公司（Roche Molecular Systems Inc.）的Vice President，该公司是一家广泛的医疗诊断产品，测试，平台和技术的开发商，制造商和供应商。在此之前，Tablak先生于2011年8月至2015年9月被Roche Molecular收购期间担任Geneweave Biosciences Inc.（传染病监测和检测平台的设计师和生产商）的董事长兼首席执行官。Tablak先生在加州大学圣巴巴拉分校（University of California，Santa Barbara）获得商业经济学学士学位。
Steve Tablak has served as a member of our board of directors since December 2019. Mr. Tablak has served as a member of the board of directors of Inflammatix, Inc., a molecular diagnostics company, since August 2017. From September 2015 to February 2017 he served as the Vice President of Roche Molecular Systems Inc., a developer, manufacturer and supplier of a wide array of medical diagnostic products, tests, platforms and technologies. Prior to that, Mr. Tablak served as Chairman and Chief Executive Officer of GeneWEAVE BioSciences Inc., a designer and producer of platforms for the surveillance and detection of infectious diseases, from August 2011 until it was acquired by Roche Molecular in September 2015. Mr. Tablak received a B.A. in Business Economics from University of California, Santa Barbara. - Steve Tablak自2019年12月起担任我们的董事会成员。Tablak先生自2017年8月起担任分子诊断公司Inflamatix，Inc.的董事会成员。2015年9月至2017年2月，他担任罗氏分子系统公司（Roche Molecular Systems Inc.）的Vice President，该公司是一家广泛的医疗诊断产品，测试，平台和技术的开发商，制造商和供应商。在此之前，Tablak先生于2011年8月至2015年9月被Roche Molecular收购期间担任Geneweave Biosciences Inc.（传染病监测和检测平台的设计师和生产商）的董事长兼首席执行官。Tablak先生在加州大学圣巴巴拉分校（University of California，Santa Barbara）获得商业经济学学士学位。
- Steve Tablak has served as a member of our board of directors since December 2019. Mr. Tablak has served as a member of the board of directors of Inflammatix, Inc., a molecular diagnostics company, since August 2017. From September 2015 to February 2017 he served as the Vice President of Roche Molecular Systems Inc., a developer, manufacturer and supplier of a wide array of medical diagnostic products, tests, platforms and technologies. Prior to that, Mr. Tablak served as Chairman and Chief Executive Officer of GeneWEAVE BioSciences Inc., a designer and producer of platforms for the surveillance and detection of infectious diseases, from August 2011 until it was acquired by Roche Molecular in September 2015. Mr. Tablak received a B.A. in Business Economics from University of California, Santa Barbara.
- Tuff Yen
-
Tuff Yen自2019年3月起担任我们的董事会成员。Yen先生是Seraph Group LLC的创始人兼总裁，该公司是他在Chemical Venture Partners和Chase Capital Partners工作后于2004年创立的一家投资公司。Yen先生目前在Zeto，Inc.（一家医疗设备制造商）的董事会任职。他此前曾在生物技术公司Genentech和Amgen从事制造和新产品开发。Yen先生在加州大学伯克利分校（University of California Berkeley）获得微生物学和免疫学本科学位，并在耶鲁大学管理学院（Yale School of Management）获得工商管理硕士学位。
Tuff Yen has served as a member of our board of directors since March 2019. Mr. Yen is the founder and president of Seraph Group LLC, an investment firm he founded in 2004 after working at Chemical Venture Partners and Chase Capital Partners. Mr. Yen currently serves on the board of directors of Zeto, Inc., a medical equipment manufacturer. He previously worked at biotechnology companies Genentech and Amgen in both manufacturing and new product development. Mr. Yen received his undergraduate degree in microbiology and immunology from the University of California Berkeley and his M.B.A. from the Yale School of Management. - Tuff Yen自2019年3月起担任我们的董事会成员。Yen先生是Seraph Group LLC的创始人兼总裁，该公司是他在Chemical Venture Partners和Chase Capital Partners工作后于2004年创立的一家投资公司。Yen先生目前在Zeto，Inc.（一家医疗设备制造商）的董事会任职。他此前曾在生物技术公司Genentech和Amgen从事制造和新产品开发。Yen先生在加州大学伯克利分校（University of California Berkeley）获得微生物学和免疫学本科学位，并在耶鲁大学管理学院（Yale School of Management）获得工商管理硕士学位。
- Tuff Yen has served as a member of our board of directors since March 2019. Mr. Yen is the founder and president of Seraph Group LLC, an investment firm he founded in 2004 after working at Chemical Venture Partners and Chase Capital Partners. Mr. Yen currently serves on the board of directors of Zeto, Inc., a medical equipment manufacturer. He previously worked at biotechnology companies Genentech and Amgen in both manufacturing and new product development. Mr. Yen received his undergraduate degree in microbiology and immunology from the University of California Berkeley and his M.B.A. from the Yale School of Management.
- Erik T. Engelson
-
Erik T.Engelson自2019年3月起担任我们的总裁兼首席执行官，并担任董事会成员。Engelson先生自2018年2月起还担任风险投资公司Shangbay Capital的风险合伙人。从2016年4月至2019年2月，Engelson先生担任Arrinex，Inc.（一家治疗和医疗设备公司）的董事会成员兼顾问。2015年8月至2016年3月，Engelson先生担任医疗器械公司Medtronic plc的总经理。从2014年8月到2015年8月出售给Medtronic plc，Engelson先生担任Medina Medical，Inc.的首席执行官，该公司是一家医疗设备公司。Engelson先生目前在梦百合软件公司Aranz Medical Ltd.以及医疗设备公司Devoro Medical Inc.和Neptune Medical Inc.的董事会任职。此前，他曾任职FlowCardia，Inc.、Concentric Medical，Inc.和Arrinex，Inc.（所有治疗和医疗设备公司）的董事会。目前，Engelson先生是University of California San Diego生物工程系董事会成员，University of California San Diego Biology Dean&8217；s Leadership Council的受托人和UC San Diego Foundation的名誉受托人。Engelson先生在加州大学圣地亚哥分校（University of California，San Diego）获得微生物学学士学位和生物工程硕士学位，并在斯坦福大学商学院（Stanford Graduate School of Business）获得执行工商管理硕士学位。
Erik T. Engelson has served as our President and Chief Executive Officer and as a member of our board of directors since March 2019. Mr. Engelson has also served as a venture partner at ShangBay Capital, a venture capital company, since February 2018. From April 2016 to February 2019 Mr. Engelson was a board member and consultant to Arrinex, Inc., a therapeutic and medical device company. From August 2015 to March 2016 Mr. Engelson was a General Manager at Medtronic PLC, a medical device company. From August 2014 until its sale to Medtronic PLC in August 2015 Mr. Engelson served as the Chief Executive Officer of Medina Medical, Inc., a medical device company. Mr. Engelson currently serves on the board of directors of ARANZ Medical Ltd., a healthcare software company, and DeVoro Medical Inc. and Neptune Medical Inc., medical device companies. Previously, he served on the board of directors of FlowCardia, Inc., Concentric Medical, Inc. and Arrinex, Inc., all therapeutic and medical device companies. Currently, Mr. Engelson is a member of the University of California San Diego Bioengineering Department Board of Trustees, a Trustee of the University of California San Diego Biology Dean’s Leadership Council and a Trustee Emeritus of the UC San Diego Foundation. Mr. Engelson received a B.A. in Microbiology and an M.S. in Bioengineering from University of California, San Diego and an Executive M.B.A. from the Stanford Graduate School of Business. - Erik T.Engelson自2019年3月起担任我们的总裁兼首席执行官，并担任董事会成员。Engelson先生自2018年2月起还担任风险投资公司Shangbay Capital的风险合伙人。从2016年4月至2019年2月，Engelson先生担任Arrinex，Inc.（一家治疗和医疗设备公司）的董事会成员兼顾问。2015年8月至2016年3月，Engelson先生担任医疗器械公司Medtronic plc的总经理。从2014年8月到2015年8月出售给Medtronic plc，Engelson先生担任Medina Medical，Inc.的首席执行官，该公司是一家医疗设备公司。Engelson先生目前在梦百合软件公司Aranz Medical Ltd.以及医疗设备公司Devoro Medical Inc.和Neptune Medical Inc.的董事会任职。此前，他曾任职FlowCardia，Inc.、Concentric Medical，Inc.和Arrinex，Inc.（所有治疗和医疗设备公司）的董事会。目前，Engelson先生是University of California San Diego生物工程系董事会成员，University of California San Diego Biology Dean&8217；s Leadership Council的受托人和UC San Diego Foundation的名誉受托人。Engelson先生在加州大学圣地亚哥分校（University of California，San Diego）获得微生物学学士学位和生物工程硕士学位，并在斯坦福大学商学院（Stanford Graduate School of Business）获得执行工商管理硕士学位。
- Erik T. Engelson has served as our President and Chief Executive Officer and as a member of our board of directors since March 2019. Mr. Engelson has also served as a venture partner at ShangBay Capital, a venture capital company, since February 2018. From April 2016 to February 2019 Mr. Engelson was a board member and consultant to Arrinex, Inc., a therapeutic and medical device company. From August 2015 to March 2016 Mr. Engelson was a General Manager at Medtronic PLC, a medical device company. From August 2014 until its sale to Medtronic PLC in August 2015 Mr. Engelson served as the Chief Executive Officer of Medina Medical, Inc., a medical device company. Mr. Engelson currently serves on the board of directors of ARANZ Medical Ltd., a healthcare software company, and DeVoro Medical Inc. and Neptune Medical Inc., medical device companies. Previously, he served on the board of directors of FlowCardia, Inc., Concentric Medical, Inc. and Arrinex, Inc., all therapeutic and medical device companies. Currently, Mr. Engelson is a member of the University of California San Diego Bioengineering Department Board of Trustees, a Trustee of the University of California San Diego Biology Dean’s Leadership Council and a Trustee Emeritus of the UC San Diego Foundation. Mr. Engelson received a B.A. in Microbiology and an M.S. in Bioengineering from University of California, San Diego and an Executive M.B.A. from the Stanford Graduate School of Business.
- Debkishore Mitra
-
Debkishore Mitra自2017年11月起担任我们的首席技术官，自2014年7月起担任我们的董事会成员。Mitra博士是我们公司的联合创始人，并于2014年12月至2017年10月担任我们公司的生物医学工程师。米特拉博士获得了技术学士学位。Indian Institute of Technology，Kharagpur，India的生物技术和生化工程学位，以及University of California，Berkeley的生物医学工程博士学位。
Debkishore Mitra has served as our Chief Technology Officer since November 2017 and as a member of our board of directors since July 2014. Dr. Mitra is a co-founder of our company and was a biomedical engineer at our company from December 2014 to October 2017. Dr. Mitra received a B.Tech. in biotechnology and biochemical engineering from Indian Institute of Technology, Kharagpur, India and a Ph.D. in Biomedical Engineering from University of California, Berkeley. - Debkishore Mitra自2017年11月起担任我们的首席技术官，自2014年7月起担任我们的董事会成员。Mitra博士是我们公司的联合创始人，并于2014年12月至2017年10月担任我们公司的生物医学工程师。米特拉博士获得了技术学士学位。Indian Institute of Technology，Kharagpur，India的生物技术和生化工程学位，以及University of California，Berkeley的生物医学工程博士学位。
- Debkishore Mitra has served as our Chief Technology Officer since November 2017 and as a member of our board of directors since July 2014. Dr. Mitra is a co-founder of our company and was a biomedical engineer at our company from December 2014 to October 2017. Dr. Mitra received a B.Tech. in biotechnology and biochemical engineering from Indian Institute of Technology, Kharagpur, India and a Ph.D. in Biomedical Engineering from University of California, Berkeley.
- Lior Susan
-
Lior Susan,2015年7月至2021年7月担任Old Owlet董事会成员，自2021年7月起担任董事会主席。苏珊是风险投资公司Eclipse Ventures，LLC的创始人和管理合伙人。在2015年创立Eclipse Ventures之前，Susan先生创建并管理了跨国电子合同制造商Flex Ltd.的硬件投资和孵化平台，在那里他获得了医疗设备公司扩大制造业务的知识和经验。在从以色列搬到美国之前，苏珊是一名企业家，曾是以色列国防军特种部队的成员。Susan先生目前在私营公司Bright Machines，Inc.、Augury，Inc.、Metrolink，Inc.、Cybertoka Ltd.、Dutch Pet，Inc.、SkyRyse，Inc.、Senser，Ltd.和InsidePacket，Ltd.的董事会任职。他曾在2020年8月至2022年12月期间担任Lucira Health公司的董事。
Lior Susan served on the board of directors of Old Owlet from July 2015 to July 2021 and has been the Chairman of the Board since July 2021. Mr. San is the founder and Managing Partner of Eclipse Ventures, LLC, a venture capital firm. He also currently serves on the boards of several privately held companies, including Cerebras Systems, Inc., Bright Machines, Inc., Flex Logix, Inc., Augury, Inc., DataPelago, Inc., Metrolink, Inc., Cybertoka Ltd., Dutch Pet, Inc., Skyryse, Inc., Senser Ltd, and InsidePacket, Ltd. Prior to founding Eclipse Ventures in 2015, Mr. San founded and managed the hardware investment and incubation platform of Flex Ltd., a multinational electronics contract manufacturer, where he gained knowledge of and experience with scaling manufacturing operations for medical device companies. Before relocating to the United States from Israel, Mr. San was an entrepreneur and former member of a special forces unit within the Israel Defense Forces. - Lior Susan,2015年7月至2021年7月担任Old Owlet董事会成员，自2021年7月起担任董事会主席。苏珊是风险投资公司Eclipse Ventures，LLC的创始人和管理合伙人。在2015年创立Eclipse Ventures之前，Susan先生创建并管理了跨国电子合同制造商Flex Ltd.的硬件投资和孵化平台，在那里他获得了医疗设备公司扩大制造业务的知识和经验。在从以色列搬到美国之前，苏珊是一名企业家，曾是以色列国防军特种部队的成员。Susan先生目前在私营公司Bright Machines，Inc.、Augury，Inc.、Metrolink，Inc.、Cybertoka Ltd.、Dutch Pet，Inc.、SkyRyse，Inc.、Senser，Ltd.和InsidePacket，Ltd.的董事会任职。他曾在2020年8月至2022年12月期间担任Lucira Health公司的董事。
- Lior Susan served on the board of directors of Old Owlet from July 2015 to July 2021 and has been the Chairman of the Board since July 2021. Mr. San is the founder and Managing Partner of Eclipse Ventures, LLC, a venture capital firm. He also currently serves on the boards of several privately held companies, including Cerebras Systems, Inc., Bright Machines, Inc., Flex Logix, Inc., Augury, Inc., DataPelago, Inc., Metrolink, Inc., Cybertoka Ltd., Dutch Pet, Inc., Skyryse, Inc., Senser Ltd, and InsidePacket, Ltd. Prior to founding Eclipse Ventures in 2015, Mr. San founded and managed the hardware investment and incubation platform of Flex Ltd., a multinational electronics contract manufacturer, where he gained knowledge of and experience with scaling manufacturing operations for medical device companies. Before relocating to the United States from Israel, Mr. San was an entrepreneur and former member of a special forces unit within the Israel Defense Forces.
- Sandra A. Gardiner
-
Sandra A. Gardiner从2010年5月开始一直担任副总裁与首席财务官。加入Lucira Health, Inc.前，Gardiner女士从2009年3月开始担任Bend Research Inc.的首席财务官，这是一家专注于定义、推动、开发并商品化制药与健康科学技术的公司。她于2009年4月被选为Bend Research Inc.的董事。从2004年到2008年，Gardiner女士担任 Lipid Sciences, Inc.的首席财务官兼公司秘书，负责管理该发展期的生物技术公司的财务与行政职能部门的所有决策制定权威，该公司致力于研发治疗心脏血管的疾病和病毒感染的产品与流程。她还担任Cardima, Inc. 和Comac的多个职位，并于1988年在先进心脏血管系统（Advanced Cardiovascular Systems）开启其生物技术职业生涯，在这之前，其为Guidant的一个部门，担任几个内部审计、会计与财务部的职位。Gardiner女士在戴维斯的加利福尼亚大学获得管理经济学理学学士学位。
Sandra A. Gardiner has served as a member of Lucira Health, Inc.'s board of directors since August 2020. Ms. Gardiner has served as the Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer of Pulse Biosciences, Inc., a bioelectric medicine company, since November 2019. Prior to joining Pulse Biosciences, Ms. Gardiner served as Executive Vice President, Finance, and Chief Financial Officer of Cutera, Inc., a global provider of laser, light and other energy-based aesthetic systems, from July 2017 to November 2019. Previous to that, Ms. Gardiner served as Vice President, Finance, Chief Financial Officer and Corporate Secretary of Tria Beauty, Inc., a medical device company, from April 2015 until it was acquired in April 2017. Previous to that, Ms. Gardiner served as Vice President of Finance and Chief Financial Officer of Aptus Endosystems, Inc., a medical device company eventually acquired by Medtronic plc; Ventus Medical, Inc., a medical device manufacturer; Vermillion, Inc., a medical diagnostic company currently known as Aspira Women's Health Inc. and Lipid Sciences Inc., a biotechnology company. Ms. Gardiner serves on the board of the Valley Humane Society. Ms. Gardiner holds a B.A. in Management Economics from the University of California, Davis. - Sandra A. Gardiner从2010年5月开始一直担任副总裁与首席财务官。加入Lucira Health, Inc.前，Gardiner女士从2009年3月开始担任Bend Research Inc.的首席财务官，这是一家专注于定义、推动、开发并商品化制药与健康科学技术的公司。她于2009年4月被选为Bend Research Inc.的董事。从2004年到2008年，Gardiner女士担任 Lipid Sciences, Inc.的首席财务官兼公司秘书，负责管理该发展期的生物技术公司的财务与行政职能部门的所有决策制定权威，该公司致力于研发治疗心脏血管的疾病和病毒感染的产品与流程。她还担任Cardima, Inc. 和Comac的多个职位，并于1988年在先进心脏血管系统（Advanced Cardiovascular Systems）开启其生物技术职业生涯，在这之前，其为Guidant的一个部门，担任几个内部审计、会计与财务部的职位。Gardiner女士在戴维斯的加利福尼亚大学获得管理经济学理学学士学位。
- Sandra A. Gardiner has served as a member of Lucira Health, Inc.'s board of directors since August 2020. Ms. Gardiner has served as the Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer of Pulse Biosciences, Inc., a bioelectric medicine company, since November 2019. Prior to joining Pulse Biosciences, Ms. Gardiner served as Executive Vice President, Finance, and Chief Financial Officer of Cutera, Inc., a global provider of laser, light and other energy-based aesthetic systems, from July 2017 to November 2019. Previous to that, Ms. Gardiner served as Vice President, Finance, Chief Financial Officer and Corporate Secretary of Tria Beauty, Inc., a medical device company, from April 2015 until it was acquired in April 2017. Previous to that, Ms. Gardiner served as Vice President of Finance and Chief Financial Officer of Aptus Endosystems, Inc., a medical device company eventually acquired by Medtronic plc; Ventus Medical, Inc., a medical device manufacturer; Vermillion, Inc., a medical diagnostic company currently known as Aspira Women's Health Inc. and Lipid Sciences Inc., a biotechnology company. Ms. Gardiner serves on the board of the Valley Humane Society. Ms. Gardiner holds a B.A. in Management Economics from the University of California, Davis.
高管简历
中英对照 | 中文 | 英文- Erik T. Engelson
Erik T.Engelson自2019年3月起担任我们的总裁兼首席执行官，并担任董事会成员。Engelson先生自2018年2月起还担任风险投资公司Shangbay Capital的风险合伙人。从2016年4月至2019年2月，Engelson先生担任Arrinex，Inc.（一家治疗和医疗设备公司）的董事会成员兼顾问。2015年8月至2016年3月，Engelson先生担任医疗器械公司Medtronic plc的总经理。从2014年8月到2015年8月出售给Medtronic plc，Engelson先生担任Medina Medical，Inc.的首席执行官，该公司是一家医疗设备公司。Engelson先生目前在梦百合软件公司Aranz Medical Ltd.以及医疗设备公司Devoro Medical Inc.和Neptune Medical Inc.的董事会任职。此前，他曾任职FlowCardia，Inc.、Concentric Medical，Inc.和Arrinex，Inc.（所有治疗和医疗设备公司）的董事会。目前，Engelson先生是University of California San Diego生物工程系董事会成员，University of California San Diego Biology Dean&8217；s Leadership Council的受托人和UC San Diego Foundation的名誉受托人。Engelson先生在加州大学圣地亚哥分校（University of California，San Diego）获得微生物学学士学位和生物工程硕士学位，并在斯坦福大学商学院（Stanford Graduate School of Business）获得执行工商管理硕士学位。
Erik T. Engelson has served as our President and Chief Executive Officer and as a member of our board of directors since March 2019. Mr. Engelson has also served as a venture partner at ShangBay Capital, a venture capital company, since February 2018. From April 2016 to February 2019 Mr. Engelson was a board member and consultant to Arrinex, Inc., a therapeutic and medical device company. From August 2015 to March 2016 Mr. Engelson was a General Manager at Medtronic PLC, a medical device company. From August 2014 until its sale to Medtronic PLC in August 2015 Mr. Engelson served as the Chief Executive Officer of Medina Medical, Inc., a medical device company. Mr. Engelson currently serves on the board of directors of ARANZ Medical Ltd., a healthcare software company, and DeVoro Medical Inc. and Neptune Medical Inc., medical device companies. Previously, he served on the board of directors of FlowCardia, Inc., Concentric Medical, Inc. and Arrinex, Inc., all therapeutic and medical device companies. Currently, Mr. Engelson is a member of the University of California San Diego Bioengineering Department Board of Trustees, a Trustee of the University of California San Diego Biology Dean’s Leadership Council and a Trustee Emeritus of the UC San Diego Foundation. Mr. Engelson received a B.A. in Microbiology and an M.S. in Bioengineering from University of California, San Diego and an Executive M.B.A. from the Stanford Graduate School of Business.- Erik T.Engelson自2019年3月起担任我们的总裁兼首席执行官，并担任董事会成员。Engelson先生自2018年2月起还担任风险投资公司Shangbay Capital的风险合伙人。从2016年4月至2019年2月，Engelson先生担任Arrinex，Inc.（一家治疗和医疗设备公司）的董事会成员兼顾问。2015年8月至2016年3月，Engelson先生担任医疗器械公司Medtronic plc的总经理。从2014年8月到2015年8月出售给Medtronic plc，Engelson先生担任Medina Medical，Inc.的首席执行官，该公司是一家医疗设备公司。Engelson先生目前在梦百合软件公司Aranz Medical Ltd.以及医疗设备公司Devoro Medical Inc.和Neptune Medical Inc.的董事会任职。此前，他曾任职FlowCardia，Inc.、Concentric Medical，Inc.和Arrinex，Inc.（所有治疗和医疗设备公司）的董事会。目前，Engelson先生是University of California San Diego生物工程系董事会成员，University of California San Diego Biology Dean&8217；s Leadership Council的受托人和UC San Diego Foundation的名誉受托人。Engelson先生在加州大学圣地亚哥分校（University of California，San Diego）获得微生物学学士学位和生物工程硕士学位，并在斯坦福大学商学院（Stanford Graduate School of Business）获得执行工商管理硕士学位。
- Erik T. Engelson has served as our President and Chief Executive Officer and as a member of our board of directors since March 2019. Mr. Engelson has also served as a venture partner at ShangBay Capital, a venture capital company, since February 2018. From April 2016 to February 2019 Mr. Engelson was a board member and consultant to Arrinex, Inc., a therapeutic and medical device company. From August 2015 to March 2016 Mr. Engelson was a General Manager at Medtronic PLC, a medical device company. From August 2014 until its sale to Medtronic PLC in August 2015 Mr. Engelson served as the Chief Executive Officer of Medina Medical, Inc., a medical device company. Mr. Engelson currently serves on the board of directors of ARANZ Medical Ltd., a healthcare software company, and DeVoro Medical Inc. and Neptune Medical Inc., medical device companies. Previously, he served on the board of directors of FlowCardia, Inc., Concentric Medical, Inc. and Arrinex, Inc., all therapeutic and medical device companies. Currently, Mr. Engelson is a member of the University of California San Diego Bioengineering Department Board of Trustees, a Trustee of the University of California San Diego Biology Dean’s Leadership Council and a Trustee Emeritus of the UC San Diego Foundation. Mr. Engelson received a B.A. in Microbiology and an M.S. in Bioengineering from University of California, San Diego and an Executive M.B.A. from the Stanford Graduate School of Business.
- Daniel George
Daniel George自2020年8月起全职担任我们的首席财务官和财务主管。从2019年4月至2020年8月，George先生通过其咨询实践担任我们的首席财务官兼财务主管，他于2016年5月成立了该公司，专门为涵盖广泛专业的梦百合公司提供执行金融服务。George先生于2014年8月至2016年5月担任Avinger Inc.（一家公开上市的医疗器械公司，专门从事周边无端切除术）的财务Vice President。George从2012年6月到2014年8月担任Apnicure，Inc.（一家医疗设备公司，专门治疗睡眠呼吸暂停）顾问和财务Vice President。George从2009年3月到2012年6月在Avantis Medical Systems，Inc.（一家结肠镜可视化技术制造商）任职，担任顾问和首席财务官。George先生也是Sr.。医疗器械公司Foxhollow Technologies Inc.的财务总监，并在会计和管理咨询公司普华永道会计师事务所（PricewaterhouseCoopers LLP）从事保证和业务咨询实践。George先生拥有加州州立大学长滩分校（California State University，Long Beach）的会计和金融学B.S.学位。
Daniel George has served as part time Chief Financial Officer since September 2023. He dedicates approximately 25% of his biness time to Anebulo. He has managed his professional services practice since December 2022, specializing in providing executive financial services to healthcare companies. Mr. George served as the Chief Financial Officer and Treasurer of Lucira Health, Inc. a publicly traded medical diagnostics company ("Lucira"), on a full time basis from Augt 2020 to November 2022. Lucira filed for bankruptcy in February 2023 and was acquired by Pfizer, Inc. through a bankruptcy auction in April 2023. From April 2019 until Augt 2020, Mr. George served as Lucira's Chief Financial Officer and Treasurer through his consulting practice, which he established in May 2016, specializing in providing executive financial services to healthcare companies covering a broad range of specialties. Mr. George served as Vice President, Finance for Avinger Inc., a publicly traded medical device company specializing in peripheral atherectomy from Augt 2014 to May 2016. From June 2012 to Augt 2014, Mr. George served as a consultant and Vice President of Finance for ApniCure, Inc., a medical device company specializing in the treatment of sleep apnea. From March 2009 to June 2012, Mr. George worked for Avantis Medical Systems, Inc., a manufacturer of colonoscopy visualization technology, where he was both a consultant and Chief Financial Officer. Mr. George was also the Sr. Director of Finance at FoxHollow Technologies Inc., a publicly traded medical device company, and worked for PricewaterhoeCoopers LLP, an accounting and management consulting firm, in the assurance and biness advisory practice. Mr. George holds B.S. degrees in both Accounting and Finance from California State University, Long Beach.- Daniel George自2020年8月起全职担任我们的首席财务官和财务主管。从2019年4月至2020年8月，George先生通过其咨询实践担任我们的首席财务官兼财务主管，他于2016年5月成立了该公司，专门为涵盖广泛专业的梦百合公司提供执行金融服务。George先生于2014年8月至2016年5月担任Avinger Inc.（一家公开上市的医疗器械公司，专门从事周边无端切除术）的财务Vice President。George从2012年6月到2014年8月担任Apnicure，Inc.（一家医疗设备公司，专门治疗睡眠呼吸暂停）顾问和财务Vice President。George从2009年3月到2012年6月在Avantis Medical Systems，Inc.（一家结肠镜可视化技术制造商）任职，担任顾问和首席财务官。George先生也是Sr.。医疗器械公司Foxhollow Technologies Inc.的财务总监，并在会计和管理咨询公司普华永道会计师事务所（PricewaterhouseCoopers LLP）从事保证和业务咨询实践。George先生拥有加州州立大学长滩分校（California State University，Long Beach）的会计和金融学B.S.学位。
- Daniel George has served as part time Chief Financial Officer since September 2023. He dedicates approximately 25% of his biness time to Anebulo. He has managed his professional services practice since December 2022, specializing in providing executive financial services to healthcare companies. Mr. George served as the Chief Financial Officer and Treasurer of Lucira Health, Inc. a publicly traded medical diagnostics company ("Lucira"), on a full time basis from Augt 2020 to November 2022. Lucira filed for bankruptcy in February 2023 and was acquired by Pfizer, Inc. through a bankruptcy auction in April 2023. From April 2019 until Augt 2020, Mr. George served as Lucira's Chief Financial Officer and Treasurer through his consulting practice, which he established in May 2016, specializing in providing executive financial services to healthcare companies covering a broad range of specialties. Mr. George served as Vice President, Finance for Avinger Inc., a publicly traded medical device company specializing in peripheral atherectomy from Augt 2014 to May 2016. From June 2012 to Augt 2014, Mr. George served as a consultant and Vice President of Finance for ApniCure, Inc., a medical device company specializing in the treatment of sleep apnea. From March 2009 to June 2012, Mr. George worked for Avantis Medical Systems, Inc., a manufacturer of colonoscopy visualization technology, where he was both a consultant and Chief Financial Officer. Mr. George was also the Sr. Director of Finance at FoxHollow Technologies Inc., a publicly traded medical device company, and worked for PricewaterhoeCoopers LLP, an accounting and management consulting firm, in the assurance and biness advisory practice. Mr. George holds B.S. degrees in both Accounting and Finance from California State University, Long Beach.
- Hansgregory Charles Hartmann
Hansgregory Charles Hartmann自2021年1月起担任我们的首席运营官。2011年2月至2016年5月，哈特曼先生担任健身器材公司Fitbit，Inc.的首席运营官。Hartmann先生于2016年5月至2017年8月担任专注于虚拟现实游戏的Facebook公司Oculus VR Inc.的首席运营官。自2018年2月起，Hartmann先生通过HCH Enterprises LLC提供执行咨询和建议服务。Hartmann之前曾担任Skyline Solar Inc.（一家太阳能设备供应商）首席运营官、Barco，Inc.（一家软件公司）创意LED Vice President和总经理，Element Labs，Inc.（一家照明设备公司）运营和硬件工程Vice President，汽车GPS解决方案提供商Dash Navigation，Inc.的运营高级副总裁，计算机硬件公司OQO，Inc.的运营高级副总裁，光网络公司Wave7Optics，Inc.的运营Vice President，Force10Networks的运营Vice President，ConvergeNet Technologies，Inc.（数据存储公司）的计算机硬件开发商、运营Vice President，以及Jetfax，Inc.（互联网传真服务公司）的制造运营Vice President。在Jetfax，Inc.之前，Hartmann先生在惠普公司（Hewlett-Packard Company）担任了大约15年的各种质量，运营和营销管理职务，这是一家信息技术公司。Hartmann先生在新泽西理工学院（New Jersey Institute of Technology）获得电气工程学士学位，并在斯坦福大学（Stanford University）获得制造系统工程硕士学位。
Hansgregory Charles Hartmann has served as our Chief Operating Officer since January 2021. From February 2011 to May 2016 Mr. Hartmann served as Chief Operations Officer of Fitbit, Inc., a fitness device company. Mr. Hartmann served as Chief Operating Officer of Oculus VR Inc., a Facebook company that focuses on virtual reality gaming, from May 2016 to August 2017. Since February 2018 Mr. Hartmann has provided executive consulting and advising services through HCH Enterprises LLC. Mr. Hartmann previously served as Chief Operations Officer at Skyline Solar Inc., a supplier of solar energy equipment, Vice President and General Manager of Creative LED at Barco, Inc., a software company, Vice President of Operations and Hardware Engineering at Element Labs, Inc., a lighting equipment company, Senior Vice President of Operations at Dash Navigation, Inc., a provider of automotive GPS solutions, Senior Vice President of Operations at OQO, Inc., a computer hardware company, Vice President of Operations at Wave7 Optics, Inc., an optical networks company, Vice President of Operations at Force10 Networks, a developer of computer hardware, Vice President of Operations at ConvergeNet Technologies, Inc., a data storage company, and Vice President of Manufacturing Operations at JetFax, Inc., an internet fax services company. Prior to JetFax, Inc., Mr. Hartmann served for approximately 15 years in various quality, operations, and marketing management roles at Hewlett-Packard Company, an information technology company. Mr. Hartmann received a B.S. in Electrical Engineering from New Jersey Institute of Technology and an M.S. in Manufacturing Systems Engineering from Stanford University.- Hansgregory Charles Hartmann自2021年1月起担任我们的首席运营官。2011年2月至2016年5月，哈特曼先生担任健身器材公司Fitbit，Inc.的首席运营官。Hartmann先生于2016年5月至2017年8月担任专注于虚拟现实游戏的Facebook公司Oculus VR Inc.的首席运营官。自2018年2月起，Hartmann先生通过HCH Enterprises LLC提供执行咨询和建议服务。Hartmann之前曾担任Skyline Solar Inc.（一家太阳能设备供应商）首席运营官、Barco，Inc.（一家软件公司）创意LED Vice President和总经理，Element Labs，Inc.（一家照明设备公司）运营和硬件工程Vice President，汽车GPS解决方案提供商Dash Navigation，Inc.的运营高级副总裁，计算机硬件公司OQO，Inc.的运营高级副总裁，光网络公司Wave7Optics，Inc.的运营Vice President，Force10Networks的运营Vice President，ConvergeNet Technologies，Inc.（数据存储公司）的计算机硬件开发商、运营Vice President，以及Jetfax，Inc.（互联网传真服务公司）的制造运营Vice President。在Jetfax，Inc.之前，Hartmann先生在惠普公司（Hewlett-Packard Company）担任了大约15年的各种质量，运营和营销管理职务，这是一家信息技术公司。Hartmann先生在新泽西理工学院（New Jersey Institute of Technology）获得电气工程学士学位，并在斯坦福大学（Stanford University）获得制造系统工程硕士学位。
- Hansgregory Charles Hartmann has served as our Chief Operating Officer since January 2021. From February 2011 to May 2016 Mr. Hartmann served as Chief Operations Officer of Fitbit, Inc., a fitness device company. Mr. Hartmann served as Chief Operating Officer of Oculus VR Inc., a Facebook company that focuses on virtual reality gaming, from May 2016 to August 2017. Since February 2018 Mr. Hartmann has provided executive consulting and advising services through HCH Enterprises LLC. Mr. Hartmann previously served as Chief Operations Officer at Skyline Solar Inc., a supplier of solar energy equipment, Vice President and General Manager of Creative LED at Barco, Inc., a software company, Vice President of Operations and Hardware Engineering at Element Labs, Inc., a lighting equipment company, Senior Vice President of Operations at Dash Navigation, Inc., a provider of automotive GPS solutions, Senior Vice President of Operations at OQO, Inc., a computer hardware company, Vice President of Operations at Wave7 Optics, Inc., an optical networks company, Vice President of Operations at Force10 Networks, a developer of computer hardware, Vice President of Operations at ConvergeNet Technologies, Inc., a data storage company, and Vice President of Manufacturing Operations at JetFax, Inc., an internet fax services company. Prior to JetFax, Inc., Mr. Hartmann served for approximately 15 years in various quality, operations, and marketing management roles at Hewlett-Packard Company, an information technology company. Mr. Hartmann received a B.S. in Electrical Engineering from New Jersey Institute of Technology and an M.S. in Manufacturing Systems Engineering from Stanford University.
- Debkishore Mitra
Debkishore Mitra自2017年11月起担任我们的首席技术官，自2014年7月起担任我们的董事会成员。Mitra博士是我们公司的联合创始人，并于2014年12月至2017年10月担任我们公司的生物医学工程师。米特拉博士获得了技术学士学位。Indian Institute of Technology，Kharagpur，India的生物技术和生化工程学位，以及University of California，Berkeley的生物医学工程博士学位。
Debkishore Mitra has served as our Chief Technology Officer since November 2017 and as a member of our board of directors since July 2014. Dr. Mitra is a co-founder of our company and was a biomedical engineer at our company from December 2014 to October 2017. Dr. Mitra received a B.Tech. in biotechnology and biochemical engineering from Indian Institute of Technology, Kharagpur, India and a Ph.D. in Biomedical Engineering from University of California, Berkeley.- Debkishore Mitra自2017年11月起担任我们的首席技术官，自2014年7月起担任我们的董事会成员。Mitra博士是我们公司的联合创始人，并于2014年12月至2017年10月担任我们公司的生物医学工程师。米特拉博士获得了技术学士学位。Indian Institute of Technology，Kharagpur，India的生物技术和生化工程学位，以及University of California，Berkeley的生物医学工程博士学位。
- Debkishore Mitra has served as our Chief Technology Officer since November 2017 and as a member of our board of directors since July 2014. Dr. Mitra is a co-founder of our company and was a biomedical engineer at our company from December 2014 to October 2017. Dr. Mitra received a B.Tech. in biotechnology and biochemical engineering from Indian Institute of Technology, Kharagpur, India and a Ph.D. in Biomedical Engineering from University of California, Berkeley.
- Tamanna Prashar
Tamanna Prashar自2019年7月起担任我们的Vice President，全球供应链，运营和质量。2016年7月至2019年7月，Prashar女士担任Vyaire Medical Inc.（一家致力于呼吸护理的梦百合公司）全球供应链Vice President。2014年4月至2016年6月，Prashar女士担任分子诊断公司Cepheid-Danaher的运营执行董事。Prashar女士在伊利诺伊大学（University of Illinois）获得工业工程学士学位和硕士学位，并在明尼苏达大学（University of Minnesota）获得工商管理硕士学位。
Tamanna Prashar has served as our Vice President, Global Supply Chain, Operations and Quality since July 2019. From July 2016 to July 2019 Ms. Prashar served as Vice President, Global Supply Chain of Vyaire Medical Inc., a healthcare company dedicated to respiratory care. Ms. Prashar served as the Executive Director, Operations at Cepheid - Danaher, a molecular diagnostics company, from April 2014 to June 2016. Ms. Prashar received a B.S. and an M.S. in Industrial Engineering from University of Illinois and an M.B.A. from University of Minnesota.- Tamanna Prashar自2019年7月起担任我们的Vice President，全球供应链，运营和质量。2016年7月至2019年7月，Prashar女士担任Vyaire Medical Inc.（一家致力于呼吸护理的梦百合公司）全球供应链Vice President。2014年4月至2016年6月，Prashar女士担任分子诊断公司Cepheid-Danaher的运营执行董事。Prashar女士在伊利诺伊大学（University of Illinois）获得工业工程学士学位和硕士学位，并在明尼苏达大学（University of Minnesota）获得工商管理硕士学位。
- Tamanna Prashar has served as our Vice President, Global Supply Chain, Operations and Quality since July 2019. From July 2016 to July 2019 Ms. Prashar served as Vice President, Global Supply Chain of Vyaire Medical Inc., a healthcare company dedicated to respiratory care. Ms. Prashar served as the Executive Director, Operations at Cepheid - Danaher, a molecular diagnostics company, from April 2014 to June 2016. Ms. Prashar received a B.S. and an M.S. in Industrial Engineering from University of Illinois and an M.B.A. from University of Minnesota.
- Kelly Lewis Brezoczky
Kelly Lewis Brezoczky自2020年4月起担任我们的执行Vice President，商业化，监管，临床和业务开发。Lewis Brezoczky女士于2019年11月至2020年4月担任我们的商业运营主管。从2012年1月到2016年1月被收购，Lewis Brezoczky女士担任蝴蝶健康公司（Butterfly Health，Inc.）的首席执行官，这是一家由她创立的女性个人产品公司。2010年之前，刘易斯·布雷佐茨基曾担任Aviron的顾问，Aviron是一家生物技术疫苗开发商，后被MedImmune收购，MedImmune是制药公司AstraZeneca PLC、实验室仪器制造公司安捷伦科技公司和Zosano Pharma Corp的子公司安捷伦实验室（Agilent Labs）的前研究与开发部门，一家生物制药公司。她曾在《国际临床实践杂志》（International Journal of Clinical Practice）上发表同行评议论文，并于2015年以来在斯坦福拜尔斯生物设计中心（Stanford Byers Center for BioDesign）进行客座演讲。Lewis Brezoczky女士目前还担任Los Gatos High School New Millennium Foundation的总裁兼董事会主席，并自2015年以来一直作为董事会成员参与该基金会。Lewis Brezoczky女士学习国际研究，被选为北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）的北卡罗莱纳研究员。
Kelly Lewis Brezoczky has served as our Executive Vice President, Commercialization, Regulatory, Clinical and Business Development since April 2020. From November 2019 to April 2020 Ms. Lewis Brezoczky served as our Head of Commercial Operations. From January 2012 until its acquisition in January 2016 Ms. Lewis Brezoczky served as Chief Executive Officer of Butterfly Health, Inc., a women’s personal products company that she founded. Prior to 2010 Ms. Lewis Brezoczky served as a consultant for Aviron, a biotech vaccine developer later acquired by MedImmune, a former research and development arm of AstraZeneca PLC, a pharmaceutical company, Agilent Labs, a division of laboratory instrument manufacturing company Agilent Technologies, Inc. and Zosano Pharma Corp, a biopharmaceutical company. She has published peer-reviewed papers in the International Journal of Clinical Practice and has guest lectured at the Stanford Byers Center for Biodesign since 2015. Ms. Lewis Brezoczky also currently serves as President and Chairman of the Board of the Los Gatos High School New Millennium Foundation and has been involved with the foundation as a board member since 2015. Ms. Lewis Brezoczky studied International Studies and was selected as a North Carolina Fellow at the University of North Carolina at Chapel Hill.- Kelly Lewis Brezoczky自2020年4月起担任我们的执行Vice President，商业化，监管，临床和业务开发。Lewis Brezoczky女士于2019年11月至2020年4月担任我们的商业运营主管。从2012年1月到2016年1月被收购，Lewis Brezoczky女士担任蝴蝶健康公司（Butterfly Health，Inc.）的首席执行官，这是一家由她创立的女性个人产品公司。2010年之前，刘易斯·布雷佐茨基曾担任Aviron的顾问，Aviron是一家生物技术疫苗开发商，后被MedImmune收购，MedImmune是制药公司AstraZeneca PLC、实验室仪器制造公司安捷伦科技公司和Zosano Pharma Corp的子公司安捷伦实验室（Agilent Labs）的前研究与开发部门，一家生物制药公司。她曾在《国际临床实践杂志》（International Journal of Clinical Practice）上发表同行评议论文，并于2015年以来在斯坦福拜尔斯生物设计中心（Stanford Byers Center for BioDesign）进行客座演讲。Lewis Brezoczky女士目前还担任Los Gatos High School New Millennium Foundation的总裁兼董事会主席，并自2015年以来一直作为董事会成员参与该基金会。Lewis Brezoczky女士学习国际研究，被选为北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）的北卡罗莱纳研究员。
- Kelly Lewis Brezoczky has served as our Executive Vice President, Commercialization, Regulatory, Clinical and Business Development since April 2020. From November 2019 to April 2020 Ms. Lewis Brezoczky served as our Head of Commercial Operations. From January 2012 until its acquisition in January 2016 Ms. Lewis Brezoczky served as Chief Executive Officer of Butterfly Health, Inc., a women’s personal products company that she founded. Prior to 2010 Ms. Lewis Brezoczky served as a consultant for Aviron, a biotech vaccine developer later acquired by MedImmune, a former research and development arm of AstraZeneca PLC, a pharmaceutical company, Agilent Labs, a division of laboratory instrument manufacturing company Agilent Technologies, Inc. and Zosano Pharma Corp, a biopharmaceutical company. She has published peer-reviewed papers in the International Journal of Clinical Practice and has guest lectured at the Stanford Byers Center for Biodesign since 2015. Ms. Lewis Brezoczky also currently serves as President and Chairman of the Board of the Los Gatos High School New Millennium Foundation and has been involved with the foundation as a board member since 2015. Ms. Lewis Brezoczky studied International Studies and was selected as a North Carolina Fellow at the University of North Carolina at Chapel Hill.